<DOC>
	<DOC>NCT02661451</DOC>
	<brief_summary>The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as compared with OHFT.</brief_summary>
	<brief_title>Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1. NYHA class ≥ 2 2. NTproBNP &gt; 1500 pg/mL (or BNP &gt; 400 pg/mL) or hospitalization for HF within the last year 3. Under appropriate guidelinedirected HF therapy (including cardiac resynchronization therapy) for a minimum of 3 months. 4. Moderate AS defined by (all must be met): Mean transaortic gradient (MG) ≥ 20 mmHg and &lt; 40 mmHg at rest and with dobutaminestress echocardiography (DSE) Aortic valve area (AVA) &gt; 1.0 cm2 with DSE Aortic valve area (AVA) ≤1.5 cm2 at rest 5. Left ventricular (LV) ejection fraction (EF) &lt; 50% 6. Anatomically suitable for transfemoral TAVR with the SAPIEN 3 THV 1. LVEF &lt; 20% or persistent need for intravenous inotropic support 2. Hospitalization for acute decompensated HF within 2 weeks prior to randomization 3. Cardiac resynchronization therapy device implantation within 3 months prior to randomization 4. Coronary artery revascularization (PCI or CABG) within 3 months prior to randomization 5. In need and suitable for revascularization per heart team consensus 6. Severe aortic regurgitation 7. Congenital unicuspid or congenital bicuspid aortic valve 8. Concomitant nonaortic valvular disease with a formal indication for valve surgery per established guidelines (ESC/ACC/AHA) 9. Previous aortic valve replacement (mechanical or bioprosthetic) 10. Severe mitral regurgitation due to degenerative mitral disease (primary MR) 11. Previous stroke with permanent disability (modified Rankin score ≥ 2) 12. Chronic obstructive pulmonary disease GOLD 4 13. Severe chronic kidney disease: glomerular filtration rate &lt; 30 mL/min by MDRD or need for renal replacement therapy 14. Gastrointestinal bleeding within the past 3 months 15. Liver cirrhosis ChildPugh C 16. Active systemic infection, including active endocarditis 17. Unwilling to accept blood transfusion 18. Evidence of intracardiac mass, thrombus, or vegetation 19. Absence of minimum amount of aortic valve calcification necessary for TAVR with the SAPIEN 3 THV 20. Hypersensitivity or contraindication to clopidogrel, aspirin, or to oral anticoagulation if indicated (eg, subject in atrial fibrillation). 21. Sensitivity to contrast media which cannot be adequately premedicated 22. Women of childbearing potential 23. Clinical signs of dementia 24. Other medical, social, or psychological conditions that precludes appropriate consent and followup 25. Life expectancy &lt; 2 years due to cancer or other noncardiac chronic diseases 26. Unwillingness to undergo followup investigations 27. Currently participating in an investigational drug or another device trial that has not reached its primary endpoint (excluding registries).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Valve</keyword>
</DOC>